Related Experiment Video
Updated: Jan 8, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Recent advances in antidiabetic marine-derived bioactive peptides: production, therapeutic targets,
Yan Fang1,2, Samira Alahyaribeik1, Mahdieh Nadali Hazaveh1
1Center for Food Biotechnology and Microbiology, Ghent University Global Campus, Incheon, South Korea.
None:
Type 2 diabetes mellitus (T2DM) has become a serious and growing public health concern. Marine-derived bioactive peptides (MDBPs), characterized by structural diversity and a high content of hydrophobic amino acids, offer a valuable reservoir for identifying novel antidiabetic compounds. This work aims to explore the T2DM therapeutic potential of MDBPs. It provides an overview preparation of MDBPs, and investigates their interactions with key therapeutic targets in T2DM, and examines their structure-activity relationships. Additionally, safety considerations of MDBPs and strategies for improving bioavailability of MDBPs are addressed. MDBPs contribute to T2DM management by modulating key metabolic enzymes through hydrogen bonding and hydrophobic interactions, thereby influencing glucose metabolism and insulin signaling. The therapeutic potential of MDBPs is influenced by intrinsic factors such as peptide sequence, molecular weight, and hydrophobicity, which determine stability, bioactivity, and target specificity. Advanced delivery systems, including microencapsulation and nanocarriers, have been employed to enhance their bioavailability and controlled release. However, rigorous safety evaluations and clinical studies remain essential to facilitate their successful translation into viable therapeutic options for T2DM.
More Related Videos
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Bioavailability Enhancement: Drug Permeability Enhancement
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Dipeptidyl Peptidase 4 Inhibitors
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems